Alaunos Therapeutics ( (TCRT) ) just unveiled an update.
On April 13, 2025, Alaunos Therapeutics‘ Board of Directors decided to receive their deferred board service fees in equity instead of cash, as per the company’s policy. The deferred fees, totaling $139,000 from late 2024 to early 2025, were compensated with 38,269 shares of common stock and 10,904 stock options, reflecting a strategic move to align the board’s interests with the company’s performance.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics is in a challenging financial position due to ongoing losses and negative cash flows. While technical indicators suggest positive momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock. The absence of debt provides some financial flexibility, but the need for external funding remains a critical concern.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
YTD Price Performance: 27.41%
Average Trading Volume: 492,780
Technical Sentiment Signal: Buy
Current Market Cap: $4.02M
Find detailed analytics on TCRT stock on TipRanks’ Stock Analysis page.